DETERA Therapeutics

DETERA Therapeutics is a preclinical stage bio-pharmaceutical company developing transformative therapies for rare kidney diseases. Their lead drug candidate, DTR8, is a first-in-class disease-modifying drug for Crescentic Glomerulonephritis (CGN), aiming to stop kidney degradation and preserve kidney function.